SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

S12 - MS Therapeutics and MRI Outcomes

Event Time: Monday April 24, 2017 1:00 pm to 3:00 pm
Topic(s): MS and CNS Inflammatory Disease
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Program Speakers - Tentative

Start/End Time Title Faculty
2:35 PM - 3:00 PM Discussion Jiwon Oh MD 

Disclosures

Speaker Disclosure
Jiwon Oh, MD Consulting or speaking fees (Biogen Idec, EMD Serono, Genzyme, Novartis, Roche, Teva). Grant/research support ( MS Society of Canada, National MS Society, Biogen Idec, Genzyme).

Abstract Presenters

Start Time Pub. Title Presenter
1:00 PM 001 Daclizumab Reduced Brain Tissue Loss Compared With Intramuscular Interferon Beta-1a in the 2-3 Year DECIDE Study John Rose, MD, FAAN
Disclosure:
Dr. Rose has received research support from Biogen.

1:12 PM 002 MRI Outcomes at Seven Years in Relapsing-Remitting Multiple Sclerosis Patients Treated With Delayed-release Dimethyl Fumarate in DEFINE, CONFIRM, and ENDORSE Douglas L Arnold, MD
Disclosure:
Dr. Arnold has received personal compensation for activities with Bayer, Biogen, Coronado Biosciences, Consortium of Multiple Sclerosis Centers, Eli Lilly, EMD Serono, Genentech, Genzyme, GlaxoSmithKline, Merck Serono, MS Forum, NeuroRx Research, Novartis, Opexa Therapeutics, Roche, S.A. Serono Symposia International Foundation, Teva, the Canadian Institutes of Health Research, and the Multiple Sclerosis Society of Canada.

1:24 PM 003 Alemtuzumab Reduces the Rate of Brain Volume Loss in RRMS Patients Over 4 Years Following Switch From SC IFNB-1a: CARE-MS Extension Study Daniel Pelletier, MD
Disclosure:
Dr. Pelletier has received personal compensation for activities with CNS Imaging Consultant, LLC as a consultant.

1:36 PM 004 Feasibility of brain atrophy measurement in clinical routine: Results from MS-MRIUS, a longitudinal observational, multicenter real-world outcome study in RRMS patients Michael Dwyer, MD, PhD
Disclosure:
Dr. Zivadinov has received personal compensation for activities with EMD Serono, Genzyme, Novartis, for speaking and consultant fees. Dr. Zivadinov has received personal compensation in an editorial capacity for BioMed Research International, BMC Medicine, BMC Neurology, Clinical CNS Drugs, Conf Pap Neurosci, Journal of Alzheimer's Disease, Vein and Lymphatics, and Word J Surg Proc. Dr. Zivadinov has received research support from Biogen Idec, Claret Medical, Genzyme, Intekrin-Coherus, Novartis, and Teva Pharmaceuticals.

1:48 PM 005 Brain Volume Loss Correlates With Long-term Disability Worsening in Patients With MS: SIENA Analysis of TEMSO MRI Data Till Sprenger
Disclosure:
Dr. Sprenger have received personal compensation for activities with Biogen Idec, Eli Lilly, Allergan, Actelion, ATI, Mitsubishi Pharma, Novartis, and Sanofi Genzyme. Dr. Sprenger received research support from Novartis Pharmaceuticals Switzerland, Swiss MS Society, and Swiss National Science Foundation.

2:00 PM 006 Alemtuzumab Decreased MRI Disease Activity Through 6 Years in Patients With Highly Active RRMS and an Inadequate Response to Prior Therapy: CARE-MS II Extension Study Alex Rovira
Disclosure:
Dr. Rovira has received personal compensation for activities with Genzyme, Novartis, Biogen, Bracco, and Teva.

2:12 PM 007 Alemtuzumab Decreased MRI Disease Activity Over 4 Years in Patients Who Switched From SC IFNB-1a: CARE-MS II Extension Study 4-Year Follow-up Daniel Pelletier, MD
Disclosure:
Dr. Pelletier has received personal compensation for activities with CNS Imaging Consultant, LLC as a consultant.

2:24 PM 008 Rapid Onset of Ocrelizumab Suppression of Brain MRI Activity in Relapsing-Remitting Multiple Sclerosis Frederik Barkhof
Disclosure:
Dr. Barkhof has received personal compensation for activities with Bayer Schering Pharma, Biogen Idec, Sanofi Genzyme, Janssen Research, Merck Serono, Novartis, Roche, Synthon BV, and Teva Neuroscience as a consultant or a speaker.

Register Now

Related Courses

Saturday April 21, 2018

9:30 AM-11:30 AM
C11 Treatment of Pediatric Multiple Sclerosis in the Current Era Brenda Banwell MD, FAAN

Sunday April 22, 2018

7:00 AM-9:00 AM
C33 Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making Aaron Miller MD, FAAN
3:30 PM-5:30 PM
C57 Spanish: Update on MS Therapy Lilyana Amezcua MD

Tuesday April 24, 2018

7:00 AM-9:00 AM
C97 Multiple Sclerosis Overview I: Clinical Pearls John Corboy MD, FAAN
1:00 PM-3:00 PM
C107 Multiple Sclerosis Overview II: Clinical Advances Scott Newsome DO, FAAN
3:30 PM-5:30 PM
C121 Multiple Sclerosis Overview III: Basic and Translational Science Michael Racke MD

Wednesday April 25, 2018

7:00 AM-9:00 AM
C135 Multiple Sclerosis Therapy: Disease-modifying Treatment I David Jones MD
9:15 AM-11:30 AM
PL5 Frontiers in Neuroscience Plenary Session
1:00 PM-3:00 PM
C146 Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
3:30 PM-5:30 PM
C161 Multiple Sclerosis Therapy: Symptom Management Jonathan Carter MD

Thursday April 26, 2018

7:00 AM-9:00 AM
C174 Clinical Pearls in Autoimmune Neurology: Real World Cases Stacey Clardy MD, PhD
1:00 PM-3:00 PM
N5 Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis Eric Klawiter MD,
Ellen Mowry MD, FAAN

Friday April 27, 2018

1:00 PM-3:00 PM
C223 Neuromyelitis Optica Spectrum Disorders Dean Wingerchuk MD, FAAN

MEMBER LOG IN

Forgot Password?